Efficacy of apatinib combined with FOLFIRI in the first-line treatment of patients with metastatic colorectal cancer
Conclusion. Apatinib combined with FOLFIRI for the first-line treatment of advanced unresectable mCRC showed good efficacy and safety. The baseline NLR was predictive of efficacy, and a low baseline NLR (HR: 0.2895, P = 0.0084) was associated with improved OS.Clinical Research Registration Number: ChiCTR1800015308.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Cancer | Cancer & Oncology | Colorectal Cancer | Diarrhoea | Drugs & Pharmacology | Hypertension | Investigational New Drugs | Toxicology